Analysts Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $15.40

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been assigned an average rating of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $15.40.

ANRO has been the topic of several recent research reports. HC Wainwright started coverage on shares of Alto Neuroscience in a research report on Monday, April 7th. They set a “buy” rating and a $10.00 target price on the stock. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a report on Friday, March 21st.

Alto Neuroscience Trading Down 0.2 %

Shares of ANRO stock opened at $2.25 on Tuesday. The stock’s 50-day moving average price is $2.74 and its 200-day moving average price is $4.63. Alto Neuroscience has a 12-month low of $1.60 and a 12-month high of $17.55. The stock has a market capitalization of $60.78 million, a price-to-earnings ratio of -0.88 and a beta of 2.16. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.09. Equities research analysts predict that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Trading of Alto Neuroscience

A number of large investors have recently made changes to their positions in ANRO. Wells Fargo & Company MN boosted its position in Alto Neuroscience by 40.0% in the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock valued at $46,000 after buying an additional 3,139 shares during the period. BNP Paribas Financial Markets increased its holdings in Alto Neuroscience by 619.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after purchasing an additional 3,715 shares during the period. Deutsche Bank AG lifted its holdings in shares of Alto Neuroscience by 31.3% in the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock worth $64,000 after buying an additional 3,629 shares during the period. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Alto Neuroscience during the 4th quarter worth $74,000. Finally, Jane Street Group LLC increased its stake in shares of Alto Neuroscience by 72.0% during the fourth quarter. Jane Street Group LLC now owns 18,600 shares of the company’s stock valued at $79,000 after buying an additional 7,783 shares during the period.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.